Market Cap: $29.31B
II
Illumina, Inc.
ILMN
NASDAQ (NASDAQ Global Select)USD
Market Cap: $29.31B
Illumina Inc (Ticker: ILMN) reinforces its commitment to innovation and growth by expanding its board of directors, adding esteemed pharmaceutical expert Daniel M. Skovronsky, M.D., Ph.D. With his exp…
Illumina strengthens its leadership in genomics with the recent appointment of Dr. Daniel M. Skovronsky (MD, PhD) to its Board of Directors, effective June 16, 2026. As the Chief Scientific and Produc…
Illumina (Ticker: ILMN) strengthens its leadership in the genomics space with the recent appointment of Dr. Daniel M. Skovronsky to its Board of Directors. This strategic move reflects the company's o…
Illumina Inc (Ticker: ILMN) continues to push the boundaries of genomic research with the launch of its StrataMap Spatial Solution, a cutting-edge platform that enhances sequencing-based spatial trans…
In a strategic move to enhance its offerings in the oncology sequencing sector, Illumina, Inc. (Ticker: ILMN) forges a significant partnership with Integrated DNA Technologies (IDT). This collaboratio…
Illumina Inc (Ticker: ILMN) strengthens its commitment to oncology with the recent launch of a novel molecular residual disease (MRD) research kit. Announced on May 28, 2026, this solution is the firs…
Illumina Inc. (Ticker: ILMN) has published its 2025 Corporate Responsibility Report, highlighting its dedication to enhancing global access to genomics and achieving ambitious sustainability milestone…
Illumina Welcomes New Leadership Ahead of Shareholders' Meeting Illumina, Inc. announces notable changes to its Board of Directors as it gears up for its annual shareholders' meeting scheduled for lat…
Illumina and the Rise of AI-Driven Oncology Solutions Illumina, a leader in genomic sequencing technologies, finds itself at the forefront of a rapidly evolving healthcare landscape, particularly in o…
Illumina and Labcorp Join Forces to Transform Precision Oncology On March 18, 2026, Illumina, Inc. and Labcorp announced a significant enhancement to their collaboration, focusing on revolutionizing p…
### Advancing Preventive Healthcare: Illumina's Collaboration with Veritas Genetics Illumina, Inc. recently announces a strategic collaboration with Veritas Genetics, backed by Fuze Health, that aims…
Illumina and Veritas Forge a New Path in Preventive Genomics In a groundbreaking initiative, Illumina, Inc. partners with Veritas Genetics, supported by Fuze Health, to integrate whole-genome sequenci…
Illumina Partners with Veritas Genetics to Redefine Preventive Genomics Illumina, Inc. announces a pivotal partnership with Veritas Genetics, facilitated by Fuze Health, aimed at revolutionizing the i…
Illumina's Alliance for Genomic Discovery Expands with Key Collaborations Illumina, Inc. advances its mission to revolutionize patient care through its Alliance for Genomic Discovery (AGD) by announci…
Illumina and Nashville Biosciences Forge New Frontiers in Genomic Research Illumina, Inc. and Nashville Biosciences, LLC announce a pivotal expansion of the Alliance for Genomic Discovery (AGD), a col…
Illumina and Nashville Biosciences Expand Genomic Discovery Alliance Illumina, Inc. collaborates with Nashville Biosciences, LLC to announce pivotal advancements in the Alliance for Genomic Discovery…
Illumina Partners with Florida Institute for Pediatric Rare Diseases to Enhance Diagnostics Illumina, Inc. announces a significant collaboration with the Florida Institute for Pediatric Rare Diseases…
Illumina Advances Oncology Research with Multiomics Solutions At the AGBT conference on February 25, 2026, Illumina, Inc. showcases transformative breakthroughs in oncology research through its innova…
Revolutionizing Genetic Analysis: Illumina's TruPath™ Genome Launch Illumina, Inc. introduces the TruPath™ Genome, a cutting-edge solution in whole genome sequencing that promises to transform the lan…
Illumina Innovates the NovaSeq X System to Enhance Sequencing Efficacy Illumina unveils an ambitious 18-month roadmap for its NovaSeq X system, targeting a range of innovations designed to significant…
Illumina unveils 18-month NovaSeq X upgrade roadmap Illumina is rolling out an 18-month roadmap of software, chemistry and consumable upgrades for its NovaSeq X high-throughput sequencer, aiming to bo…
Headline: Illumina maps 18-month upgrade cadence to boost NovaSeq X capacity and accuracy NovaSeq X upgrade plan targets higher throughput and Q70 accuracy Illumina unveils an 18-month roadmap of soft…
Illumina leans on clinical NGS momentum and SomaLogic deal Guidance and acquisition shape 2026 growth plan Illumina is positioning revenue growth for fiscal 2026 around expanding clinical uptake of ne…
Illumina links Frozen Zoo’s five-decade archive to modern genomics Illumina is announcing a large-scale sequencing collaboration with the San Diego Zoo Wildlife Alliance’s Frozen Zoo, aiming to conver…
Illumina Launches Groundbreaking Billion Cell Atlas to Transform Drug Discovery Illumina, Inc. has unveiled the Billion Cell Atlas, the world’s largest genome-wide genetic perturbation dataset, markin…
Illumina Appoints Renowned Genomics Leader as Chief Medical Officer Illumina, Inc. announces the appointment of Dr. Eric D. Green, a distinguished figure in the field of genomics, as its new Chief Med…
Illumina Unveils Cloud-Based Multiomics Platform to Simplify Biological Data Integration Illumina, Inc. introduces the Illumina Connected Multiomics, a cutting-edge, cloud-based research software plat…
Illumina's Short Interest Surge: Implications for Market Sentiment and Strategic Response Illumina Inc. faces an uptick in short interest, reflecting a shift in investor sentiment around the company.…
Illumina Faces Increasing Short Interest Amid Market Sentiment Shifts Illumina Inc., a leader in genomics and DNA sequencing technology, currently navigates a significant uptick in short interest, whi…
Illumina Faces Growing Investor Skepticism Amid Rising Short Interest Illumina Inc., a leader in genetic sequencing technology, currently experiences a significant uptick in short interest, which has…
Illumina Partners with MyOme to Transform Precision Medicine Landscape Illumina, Inc. announces a strategic collaboration with MyOme, a leader in clinical whole genome sequencing and analysis. This pa…
Illumina and MyOme Unite to Transform Genomic Medicine Illumina, Inc. embarks on a pivotal collaboration with MyOme, a clinical platform specializing in whole genome sequencing (WGS) and analysis. Thi…
L&T Technology Services Unveils AI-Powered Digital Twin Platform for Respiratory Health L&T Technology Services (LTTS) announces the launch of a groundbreaking artificial intelligence (AI)-powered dig…
Advancing Respiratory Diagnostics with AI: L&T Technology Services Unveils a Cutting-Edge Platform L&T Technology Services introduces an innovative artificial intelligence-powered digital twin platfor…
Illumina's Competitive Edge in Life Sciences Amidst Industry Trends Illumina, a leader in genomic sequencing and biotechnology, continues to strengthen its position in the life sciences market by focu…
Illumina's Leading Role in Genomic Research and Disease Understanding Illumina, Inc. continues to solidify its position as a pioneer in the field of genomics, particularly through its advancements in…
Illumina Protein Prep: Transforming Access to Proteomics Research Illumina, Inc. has introduced its groundbreaking product, Illumina Protein Prep, which is revolutionizing the field of proteomics for…
Illumina Unveils Protein Prep to Revolutionize Proteomics Accessibility Illumina, Inc. has launched its groundbreaking Illumina Protein Prep, a novel solution that significantly advances the accessibi…
Illumina Welcomes Lifting of Export Ban by China On November 5, 2025, the Chinese Ministry of Commerce (MOFCOM) announces the lifting of an export ban on Illumina, Inc., effective November 10, 2025. T…
Illumina's Path Forward: Export Ban Lifted Amidst Regulatory Challenges Illumina, Inc., a leading player in the DNA sequencing and array-based technologies sector, marks a pivotal moment in its operat…
Illumina's Steady Performance Amidst Industry Challenges Illumina, Inc. reports its financial results for Q3 2025, revealing stable revenue of $1.08 billion, unchanged from Q3 2024. The company achiev…
Illumina's Strategic Position in a Competitive Market Landscape Illumina, a leader in genomic sequencing and array-based technologies, continues to solidify its position within the biotech industry as…
Illumina: Advancing Genomic Innovation in a Competitive Landscape Illumina stands at the forefront of the genomics industry, driving innovation in next-generation sequencing (NGS) technology. As the d…
Illumina’s Shift in Market Sentiment Signals Potential Growth Opportunities Illumina Inc. experiences a significant shift in market sentiment as its short interest declines by 10.0% from the previous…
Illumina’s Shift in Market Sentiment: Decreasing Short Interest Signals Optimism Illumina Inc. (NYSE: ILMN), a leader in genomic sequencing and biotechnology, experiences a significant shift in market…
Revolutionizing Genetic Testing: Illumina's Advanced Technologies in Healthcare Illumina, Inc. has recently introduced groundbreaking technologies that are set to transform the landscape of genomic te…
Illumina's Market Performance: Navigating Analyst Perspectives In recent months, Illumina (NASDAQ: ILMN) attracts significant attention within the biotechnology sector, as nine analysts provide a rang…
Illumina Launches BioInsight to Propel Life Sciences Innovations Illumina, Inc. has unveiled BioInsight, a new business unit dedicated to advancing innovations in life sciences through the integration…
Strengthening Domestic Medical Supply Chains: A National Imperative In light of recent global health crises, the U.S. Commerce Department re-evaluates the nation's dependence on foreign suppliers for…
Illumina Partners with Pharmaceutical Companies to Advance Precision Oncology through KRAS Biomarker Testing Illumina Inc. has announced a strategic collaboration with several global pharmaceutical co…